Tonix Pharmaceuticals (TNXP) said Monday it reached an agreement with a second major group purchasing organization to provide coverage for its sublingual tablet Tonmya for fibromyalgia.
The new contract extends treatment access to approximately 17 million more commercial lives in the US, the company said.
Combined with a previous contract, the drug is now covered for nearly 52 million commercial lives, and is also accessible in the majority of states through Medicaid programs encompassing roughly 75 million individuals, Tonix said.
Shares of the company were up 5.6% in Monday premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments